Complement function in mAb-mediated cancer immunotherapy
- 31 March 2004
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 25 (3), 158-164
- https://doi.org/10.1016/j.it.2004.01.008
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activitiesImmunology, 2000
- Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated AttackPublished by Elsevier BV ,2000
- A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated DamageLaboratory Investigation, 2000
- Regulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/αMβ2 - lntegrin GlycoproteinCritical Reviews in Immunology, 2000
- Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumoursEuropean Journal of Cancer, 1999
- Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cellsGastroenterology, 1996
- Distribution of C3-Step Regulatory Proteins of the Complement System, CD35 (CRl), CD46 (MCP), and CD55 (DAF), in Hematological MalignanciesLeukemia & Lymphoma, 1994
- Complement killing of human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)'2-cobra venom factor conjugate are equally cytotoxicMolecular Immunology, 1990